Lars Wortmann

Lars Wortmann is a Senior Principal Scientist at Boehringer Ingelheim since May 2020, focusing on medicinal chemistry for NASH and obesity. Previously, Lars served as a Principal Scientist and Lab and Project Team Leader at Boehringer Ingelheim, concentrating on NASH. Between January 2007 and April 2020, Lars worked at Bayer Pharmaceuticals as a Senior Scientist and Lab and Project Team Leader, specializing in medicinal chemistry for oncology, particularly immuno-oncology, DNA-repair, and oncogenic signaling, while also providing management support for Global Drug Discovery. Lars's earlier experience includes a position as a Scientist and Lab and Project Team Leader at Schering AG, where the focus was on medicinal chemistry for oncology, gynecological therapy, and contraception. Lars holds a Postdoctoral Studies degree from Stanford University, a Dr. rer. nat. in Stereoselective Organic Chemistry from RWTH Aachen University, and a Dipl.-Chem. in Chemistry from Goethe University Frankfurt.